Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 144

Sort by

Sort Order Select

Journal Articles

Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial

Blood blood.2025031313.

https://doi.org/10.1182/blood.2025031313

Published: 2025

Includes: Supplemental data

Journal Articles

Longterm survival and late effects following hematopoietic cell transplantation for sickle cell disease into a modern era: A center for international blood and marrow transplant research (CIBMTR) analysis

Elizabeth Stenger, Ruta Brazauskas, Andrew Peterson, Stephanie Bo-Subait, Minoo Battiwalla, David Buchbinder, Betty K. Hamilton, Bipin Savani, Helene Schoemans, Michelle Schoettler, Mohamed Sorror, Rachel Phelan, Shalini Shenoy, Lakshmanan Krishnamurti

Blood (2025) 146 (Supplement 1): 1051.

https://doi.org/10.1182/blood-2025-1051

Published: 2025

Journal Articles

Infection risk factors and burden in patients treated with T-cell engaging bispecific antibodies for relapsed B-cell lymphoma and multiple myeloma

Blood (2025) 146 (Supplement 1): 2814.

https://doi.org/10.1182/blood-2025-2814

Published: 2025

Journal Articles

Upstream integration of implementation planning in clinical trials through the blood and marrow transplant clinical trials network

Anna Desalvo, Brittany Ragon, Neel Bhatt, Betty K. Hamilton, Azra Borogovac, Mary Horowitz, Nandita Khera, Mark Juckett, Steven Devine, Christopher Dandoy, Alla Keyzner, Yvonne Efebera, John Plastaras, Mitchell Horwitz, Sarah Wall, Valerie Stewart, Mykala Heuer, Todd Molfenter

Blood (2025) 146 (Supplement 1): 7913.

https://doi.org/10.1182/blood-2025-7913

Published: 2025

Journal Articles

Severe neutropenia after treatment with T-cell engaging bispecific antibodies is associated with higher rates of CRS and disease response

Blood (2025) 146 (Supplement 1): 6350.

https://doi.org/10.1182/blood-2025-6350

Published: 2025

Journal Articles

Orca-T improves chronic graph-versus-host disease free in patients with a broad range of demographic and clinical variables: Results of randomized, Phase 3 trial

Blood (2025) 146 (Supplement 1): 2477.

https://doi.org/10.1182/blood-2025-2477

Published: 2025

Journal Articles

Observational comparison of orca-T to registry-based post-transplant cyclophosphamide patients using matched unrelated donors

Blood (2025) 146 (Supplement 1): 6029.

https://doi.org/10.1182/blood-2025-6029

Published: 2025

Journal Articles

Cardiovascular disease risk scores as predictors of cardiovascular disease and heart failure in allogeneic hematopoietic cell transplant survivors

Victoria Stepanyants, Xuefei Jia, William Liu, Matt Kalaycio, Ronald Sobecks, Claudio Brunstein, Andrew Trunk, Christina Ferraro, Kayla Giannetti, Arianne Clare Agdamag, Betty K. Hamilton

Blood (2025) 146 (Supplement 1): 2488.

https://doi.org/10.1182/blood-2025-2488

Published: 2025

Journal Articles

Clinical and disease characteristics of initial participants at time of enrollment in THRIVE, a prospective, observational cohort study of patients at risk for chronic graft‑versus‑host disease

Catherine Lee, Doris Ponce, Zhenyi Xue, Nandita Khera, Betty K. Hamilton, Shawnta Lorthridge-Jackson, Valkal Bhatt, John Galvin, Areej El-Jawahri

Blood (2025) 146 (Supplement 1): 2446.

https://doi.org/10.1182/blood-2025-2446

Published: 2025

Journal Articles

Real-world response and toxicity profiles of sequential bispecific antibody therapies in Relapsed/Refractory multiple myeloma

Agrima Mian, Rafaella Ferreira De Araujo Litvin, Kelsey Pandrangi, Kristina Nasr, Sharan Jhaveri, Mikhaila Rice, Joslyn Rudoni, Louis Williams, Christy Samaras, John Molina, Betty K. Hamilton, Shahzad Raza, Faiz Anwer, Jason Valent, Claudio Brunstein, Brian Hill, Paolo Caimi, Sandra Mazzoni

Blood (2025) 146 (Supplement 1): 6376.

https://doi.org/10.1182/blood-2025-6376

Published: 2025

Journal Articles

Real-time interleukin-6 (IL-6) kinetics predict cytokine release syndrome (CRS) in patients receiving chimeric antigen receptor (CAR) T-cell therapy for Relapsed/Refractory B-cell malignancies

Agrima Mian, Rafaella Ferreira De Araujo Litvin, Jessica Colon-Franco, Sujata Patil, Megan Molnar, Allison Winter, Sandra Mazzoni, Robert Dean, Louis Williams, Aaron Gerds, John Molina, Shahzad Raza, Faiz Anwer, Deepa Jagadeesh, Betty K. Hamilton, Claudio Brunstein, Brian Hill, Paolo Caimi

Blood (2025) 146 (Supplement 1): 2397.

https://doi.org/10.1182/blood-2025-2397

Published: 2025

Journal Articles

A pilot study of nicotinamide riboside supplementation in allogeneic bone marrow transplantation

Ronald Sobecks, Navneet Majhail, Xiaorong Gu, Xuefei Jia, Megan Molnar, John Desamito, Dongxu Jiang, Kacey O'Donnell, Songa Bae, Craig Sauter, Andrew Trunk, Deepa Jagadeesh, Matt Kalaycio, Betty K. Hamilton, Claudio Brunstein, Jaroslaw Maciejewski, Babal Jha

Blood (2025) 146 (Supplement 1): 2437.

https://doi.org/10.1182/blood-2025-2437

Published: 2025

Journal Articles

Cytokines associated with organ manifestations in chronic graft-versus-host disease

Stephanie J. Lee, Ningxin Ma, Timothy Randolph, Carrie L. Kitko, Corey S. Cutler, Najla El Jurdi, George Chen, Betty K. Hamilton, Joseph A. Pidala, Paul A Carpenter, Sally Arai, Lynn Onstad, Sophie Paczesny, Tomoko Sekiguchi, Motoko Koyama, Geoffrey R. Hill

Blood (2024) 144 (Supplement 1): 4902.

https://doi.org/10.1182/blood-2024-203743

Published: 2024

Journal Articles

Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States

Blood (2024) 144 (Supplement 1): 4921.

https://doi.org/10.1182/blood-2024-199289

Published: 2024

Journal Articles

Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients

Blood (2024) 144 (Supplement 1): 694.

https://doi.org/10.1182/blood-2024-205917

Published: 2024

Journal Articles

Genetic Profiling and Survival Analysis of Patients with Acute Myeloid Leukemia and a History of Autoimmune Disease

Blood (2024) 144 (Supplement 1): 6127.

https://doi.org/10.1182/blood-2024-199358

Published: 2024

Journal Articles

Factors Associated with Platelet Engraftment Following Allogeneic Hematopoietic Cell Transplantation

Andrew D. Trunk, Hong Li, Matt Kalaycio, Ronald Sobecks, Claudio Brunstein, Craig S. Sauter, Betty K. Hamilton

Blood (2024) 144 (Supplement 1): 3488.

https://doi.org/10.1182/blood-2024-204051

Published: 2024

Journal Articles

Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States

Blood (2024) 144 (Supplement 1): 2170.

https://doi.org/10.1182/blood-2024-210263

Published: 2024

Journal Articles

Assessment of Secondary Malignancies after Allogeneic Hematopoietic Cell Transplant When Comparing Treatment with and without Post-Transplant Cyclophosphamide

Daniel P. Nurse, Wei Wei, Amanda Burns, Joseph Farinella, Deepa Jagadeesh, Robert M. Dean, Rabi Hanna, Seth J Rotz, Aaron T. Gerds, Claudio Brunstein, Matt Kalaycio, Craig S. Sauter, Betty K. Hamilton, Ronald Sobecks

Blood (2024) 144 (Supplement 1): 7383.

https://doi.org/10.1182/blood-2024-202626

Published: 2024

Journal Articles

Prevalence and Outcomes of Opportunistic Infections in Steroid Refractory Graft Versus Host Disease Patients Treated with Ruxolitinib, Ibrutinib, and Belumosudil

Victoria Stepanyants, Hong Li, Danielle Cenin, Jessi Edwards, Claudio Brunstein, Matt Kalaycio, Ronald Sobecks, Craig S. Sauter, Betty K. Hamilton

Blood (2024) 144 (Supplement 1): 2145.

https://doi.org/10.1182/blood-2024-199329

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial

Longterm survival and late effects following hematopoietic cell transplantation for sickle cell disease into a modern era: A center for international blood and marrow transplant research (CIBMTR) analysis

Infection risk factors and burden in patients treated with T-cell engaging bispecific antibodies for relapsed B-cell lymphoma and multiple myeloma

Upstream integration of implementation planning in clinical trials through the blood and marrow transplant clinical trials network

Severe neutropenia after treatment with T-cell engaging bispecific antibodies is associated with higher rates of CRS and disease response

Orca-T improves chronic graph-versus-host disease free in patients with a broad range of demographic and clinical variables: Results of randomized, Phase 3 trial

Observational comparison of orca-T to registry-based post-transplant cyclophosphamide patients using matched unrelated donors

Cardiovascular disease risk scores as predictors of cardiovascular disease and heart failure in allogeneic hematopoietic cell transplant survivors

Clinical and disease characteristics of initial participants at time of enrollment in THRIVE, a prospective, observational cohort study of patients at risk for chronic graft‑versus‑host disease

Real-world response and toxicity profiles of sequential bispecific antibody therapies in Relapsed/Refractory multiple myeloma

Real-time interleukin-6 (IL-6) kinetics predict cytokine release syndrome (CRS) in patients receiving chimeric antigen receptor (CAR) T-cell therapy for Relapsed/Refractory B-cell malignancies

A pilot study of nicotinamide riboside supplementation in allogeneic bone marrow transplantation

Cytokines associated with organ manifestations in chronic graft-versus-host disease

Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States

Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients

Genetic Profiling and Survival Analysis of Patients with Acute Myeloid Leukemia and a History of Autoimmune Disease

Factors Associated with Platelet Engraftment Following Allogeneic Hematopoietic Cell Transplantation

Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States

Assessment of Secondary Malignancies after Allogeneic Hematopoietic Cell Transplant When Comparing Treatment with and without Post-Transplant Cyclophosphamide

Prevalence and Outcomes of Opportunistic Infections in Steroid Refractory Graft Versus Host Disease Patients Treated with Ruxolitinib, Ibrutinib, and Belumosudil

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only